Table 1. Clinical characteristics of DLBCL patients.
| Characteristics | Total (n=161) | RDW<14.1 (n=111) | RDW≥14.1 (n=50) | P Value |
|---|---|---|---|---|
| Gender | ||||
| Male, n (%) | 91(56.5%) | 63(56.8%) | 26(52.0%) | 0.610 |
| Age | 59.1±11.4 | 58.4±11.0 | 60.8±12.4 | 0.206 |
| Ann Arbor stage, n (%) | 0.150 | |||
| I | 49(30.4%) | 30(27.0%) | 19(38.0%) | |
| II | 17(10.6%) | 10(9.0%) | 7(14.0%) | |
| III | 56(34.8%) | 39(35.1%) | 17(34.0%) | |
| IV | 39(24.2%) | 32(28.8%) | 7(14.0%) | |
| B symptoms, n (%) | 0.001 | |||
| Yes | 27(16.8%) | 11(9.9%) | 16(32.0%) | |
| No | 134(83.2%) | 100(90.1%) | 34(68.0%) | |
| ECOG PS, n (%) | 0.031 | |||
| <2 | 129(80.1%) | 94(84.6%) | 35(70.0%) | |
| ≥2 | 32(19.9%) | 17(15.4%) | 15(30.0%) | |
| Extranodal sites of disease, n (%) | 0.035 | |||
| >1 | 32(19.9%) | 17(%) | 15(30.0%) | |
| ≤1 | 129(80.1%) | 94(%) | 35(70.0%) | |
| IPI, n (%) | 0.032 | |||
| 0 | 33(20.5%) | 26(23.4%) | 7(14.0%) | |
| 1 | 60(37.3%) | 43(38.7%) | 17(34.0%) | |
| 2 | 32(19.9%) | 24(21.6%) | 8(16.0%) | |
| 3 | 23(14.3%) | 10(9.0%) | 13(26.0%) | |
| 4 | 10(6.2%) | 5(4.5%) | 5(10.0%) | |
| 5 | 3(1.9%) | 3(2.7%) | 0(0%) | |
| LDH, n (%) | 0.082 | |||
| ≤1 × ULN | 100(62.1%) | 74(66.7%) | 26(52.0%) | |
| >1 × ULN | 61(37.9%) | 37(33.3%) | 24(48.0%) | |
| Bone marrow involvement, n (%) | 0.287 | |||
| YES | 10(6.2%) | 5(4.5%) | 5(10.0%) | |
| NO | 151(93.8%) | 106(95.5%) | 45(90.0%) | |
| Pathology type | 0.843 | |||
| GCB subtype | 39(24.2%) | 26(23.4%) | 13(26%) | |
| Non-GCB subtype | 122(75.8%) | 85(76.6%) | 37(74%) | |
| Hemoglobin(g/L), mean±SD | 122.9±19.0 | 127.8±16.7 | 112.1±19.4 | <0.001 |
| RDW, mean±SD | 13.6±1.3 | 13.0±0.7 | 15.0±1.2 | <0.001 |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index; LDH, lactate dehydrogenase; PS, performance status; GCB, germinal center B cell; RDW, red blood cell distribution width.